A Phase 3 interventional study of Locoregional radiation treatment - Conventional fractionation and Locoregional radiation treatment - Hypofractionation in Breast Neoplasms, Radiotherapy and Lymphedema, sponsored by Ontario Clinical Oncology Group (OCOG). Active, not recruiting at 20 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Ontario Clinical Oncology Group (OCOG) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG) — 2 open to participants now, 4 under way, 2 of them phase 3. Breast Neoplasms · Ontario Clinical Oncology Group (OCOG).
Among the 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG), this one is the 7th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2021, is one of 5 in phase 3, and was the 22nd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →2 of the 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG) are open now, in 2 countries. Recruiting first, the newest first:
Ontario Clinical Oncology Group (OCOG) · Sites in Australia, Canada
Ages 50+ · Women only
Ontario Clinical Oncology Group (OCOG) · Sites in Australia, Canada
Ages 50–120 · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 588 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 318 across the 20 interventional studies, 426 across the 4 observational. Of the 20 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ontario Clinical Oncology Group (OCOG) is the lead sponsor of 56 studies on the registry; 4 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG), from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine if hypofractionated RT delivered over 1 week to the breast or chest wall and regional nodes (26Gy in 5 daily fractions) following BCS or mastectomy, is non-inferior to conventional fractionation to the breast or chest wall and regional nodes delivered over 3 weeks (40Gy in 15 daily fractions) in patients with node-positive breast cancer.
A multi-centre, randomized, non-inferior, phase III study comparing two radiation treatment modalities, conventional fractionation with hypofractionation for locoregional RT. Eligible, consenting patients with newly diagnosed and histologically confirmed invasive carcinoma of the breast without evidence of metastatic disease; treated with definitive surgery [BCS or mastectomy with nodal staging using sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND)] will be randomized in a 1:1 fashion to either conventional locoregional RT (control group) or hypofractionated locoregional RT (experimental group). Stratification factors include: body mass index, the performance of ALND, type of surgery (BCS or mastectomy) and clinical centre.
Study participants will be assessed for lymphedema, the primary outcome, by measuring arm volume. Arm mobility will be assessed by measuring arm movement. Study participants will be assessed for acute and late radiation toxicities, during and post RT. Study participants will be followed and assessed annually for breast cancer recurrence (BCR), new second cancers, quality of life (QOL) and overall survival. Cost effectiveness and cost utility will also be determined. The planned sample size is 588 study participants. The study will be conducted at clinical centres throughout Canada.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Candidate for locoregional radiotherapy: breast cancer stage after definitive surgery:
chemotherapy was not administered: pathologic stage T3N0,T1-3 N1-2**
** patients with nodal micromets (N1mi) are eligible
Neoadjuvant chemotherapy was administered: clinical stage T3N0, T1-3, N1-2 and pathologic stage T0-3, N0-2†
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Conventional fractionation for locoregional radiotherapy
Radiation: Locoregional radiation treatment - Conventional fractionation
Hypofractionation for locoregional radiotherapy
Radiation: Locoregional radiation treatment - Hypofractionation
40 Gray in 15 daily fractions over 3 weeks
26 Gray in 5 daily fractions over 1 week
Lymphedema
Lymphedema defined as relative volume change (RVC) ≥10%
Time frame: 3 years post randomization
Breast cancer recurrence
Both locoregional and distant recurrence and second cancers
Time frame: Annually for 5 years post randomization
Mortality
Survival
Time frame: Annually for 5 years post randomization
Radiation toxicity
Acute and late radiation toxicity
Time frame: During last week of radiotherapy, at 3 months post radiotherapy and annually for 5 years post randomization
Arm mobility
Assessed by measuring the straight lateral abduction of both the ipsilateral and contralateral arm
Time frame: 1 and 3 years post randomization
Patient Quality of Life with respect to daily health and activities
Impact on quality of life will be assessed with the European Organization for Research in Treatment of Cancer and the Breast Cancer Specific Module 23. The scale is 1 to 4 where a higher score means a worse outcome.
Time frame: During last week of radiotherapy, at 3 months post radiotherapy and 1 and 3 years post randomization
Perception of lymphedema
Impact of lymphedema on quality of life will be assessed with the National Surgical Adjuvant Breast and Bowel Project questionnaire. The scale is 1 to 5 where a higher score means a worse outcome.
Time frame: During last week of radiotherapy, at 3 months post radiotherapy and 1 and 3 years post randomization
Perception of breast cosmesis
Patient-reported breast cosmesis using a Breast Cosmesis Questionnaire to study the late effects of radiation.
Time frame: 1 and 3 years post randomization
Health Care Resource Utilization
Health Care Resource Utilization will be estimated using dates and duration of radiotherapy treatment and emergency department visits and hospitalizations.
Time frame: During radiotherapy, at 3 months post radiotherapy and annually for 5 years post randomization
Patient Costs
Patient costs will be assessed using a Time Off Work Questionnaire to study the financial impact of breast cancer and its treatment
Time frame: During last week of radiotherapy, at 3 months post radiotherapy and 1 and 3 years post randomization
Started Feb 2021 (actual). Primary completion is estimated for Jul 2028, 89 months after the start.
Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 89 months is above that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ontario Clinical Oncology Group (OCOG)